How to Scale GLP-1 Distribution Without Losing Control

Article

GLP-1 growth is a supply chain challenge, not just a demand challenge

GLP-1 therapies have moved from a specialty prescribing category to a major operational concern for pharmacies, health systems, manufacturers, and healthcare distributors. Rising use in diabetes and weight-management care has increased pressure on medication availability, injector-device handling, patient access, and last-mile delivery performance. As manufacturers add domestic production capacity and device platforms receive new market approvals, the volume of injectable therapies entering distribution networks is likely to keep expanding.

For pharmacy operations leaders, the central question is not simply whether product can be sourced. It is whether the organization can receive, store, allocate, dispense, and deliver high-demand injectable therapies without creating preventable risk. A distribution model that works during routine demand can fail quickly when allocations tighten, new dose strengths launch, cold-storage capacity fills, or patients require rapid replacement shipments.

A scalable GLP-1 supply chain requires tighter coordination across procurement, inventory control, pharmacy operations, patient support, and transportation. OnWay Logistics helps healthcare organizations design time-sensitive delivery workflows that support medication access while preserving chain of custody and operational visibility.

Understand the operational profile of injectable GLP-1 therapies

Many GLP-1 products are supplied as prefilled pens or other delivery devices, which creates a supply chain profile different from standard oral prescriptions. The drug product, delivery mechanism, packaging configuration, and patient instructions must all arrive intact. While exact storage requirements vary by manufacturer and product presentation, pharmacy teams should rely on the current FDA-approved prescribing information, product label, and manufacturer handling guidance for every SKU.

Several operational characteristics deserve special attention:

Temperature sensitivity: Many injectable therapies require refrigerated storage before dispensing. Excursions may affect product usability, but teams should never make assumptions about allowable time out of refrigeration without product-specific guidance.

High-value inventory: Shortages and strong patient demand can make individual packages expensive and difficult to replace. Inventory loss has direct financial and continuity-of-care consequences.

Device integrity: Pens and injectors are engineered products. Crushing, freezing, excessive vibration, or damaged packaging can compromise administration even if the medication appears intact.

Recurring refill patterns: Patients may need predictable monthly fulfillment. Missed refill windows can lead to therapy interruption and increased patient-service workload.

Variable allocation: Manufacturers and wholesalers may allocate product by customer, dose strength, geography, or historical purchasing patterns. Pharmacy procurement teams need a process for managing those constraints.

These realities make GLP-1 distribution a cross-functional program. Pharmacy leaders should involve purchasing, clinical pharmacy, quality, finance, IT, and transportation early rather than treating home delivery as an isolated courier task.

Build a product-specific temperature and handling program

Cold-chain discipline begins before a package reaches a courier. Organizations should map the product journey from receiving dock to final handoff, documenting every storage location, transfer point, and accountable party. This workflow should include the acceptable temperature range, packaging method, maximum anticipated transit duration, escalation criteria, and disposition process for suspected excursions.

USP does not provide one universal shipping recipe for all refrigerated medications. However, USP <1079> Good Storage and Distribution Practices for Drug Products offers a useful framework for managing temperature-controlled pharmaceuticals through documented procedures, monitoring, training, and deviation investigation. Pharmacy teams should pair that framework with each manufacturer’s labeled requirements.

Practical controls include conditioned packaging, validated coolants, tamper-evident seals, route-duration thresholds, delivery-time planning, and documented proof of delivery. For high-risk or high-cost shipments, temperature indicators or data loggers may be appropriate. The right monitoring level should be based on product risk, shipment duration, destination conditions, and the ability to intervene when a delay occurs.

Do not confuse insulated packaging with a validated cold chain. A package can look professionally packed and still fail if it sits in a hot vehicle, is left at an unsecured doorstep, or travels beyond its tested duration. A strong program measures real-world conditions and updates packaging standards when routes, seasons, or destination patterns change.

Use allocation governance to protect patient access

When supply is constrained, informal decision-making creates inconsistency and exposes pharmacies to patient dissatisfaction. Health systems should establish an allocation governance process before shortages intensify. That process should define who can approve inventory transfers, when substitutions require prescriber involvement, how backorders are communicated, and which patients receive priority consideration under clinically approved policies.

Clinical teams should lead therapeutic decisions. Supply chain teams should provide the data needed to make them responsibly. Useful indicators include days on hand by dose strength, open prescription demand, scheduled refill volume, wholesaler fill rates, expired inventory risk, and delivery failure rates. A weekly cross-functional review can identify pressure points before patients arrive for refills that cannot be filled.

Clear communication is equally important. Patients should not learn about a delayed therapy only after a failed delivery attempt. Pharmacy staff need approved scripts and escalation paths that explain next steps without making promises that the supply chain cannot support.

Separate inventory visibility from patient eligibility decisions

Inventory visibility answers whether medication is physically available, committed, in transit, or on order. Eligibility decisions determine how a limited supply is clinically allocated. Combining these functions in an ad hoc spreadsheet can create errors and difficult audit questions. Keep the data sources connected, but maintain clear ownership between supply chain and clinical governance teams.

Design last-mile delivery around patient availability

Last-mile delivery is often where a well-managed pharmacy process breaks down. A shipment may leave the pharmacy on time but become vulnerable to missed handoffs, apartment-access barriers, weather exposure, or patient confusion. For refrigerated therapy, an unattended delivery can introduce safety and quality concerns even when the route itself was efficient.

Organizations should segment delivery options based on risk. Same-day scheduled delivery may be appropriate for patients who cannot visit the pharmacy, require replacement medication quickly, or live within a defined service area. Next-day delivery may fit stable, validated lanes with dependable packaging. Pickup remains valuable for patients who prefer direct handoff or live in areas where delivery reliability is limited.

OnWay Logistics can support scheduled medical deliveries with chain-of-custody documentation, trained couriers, and real-time shipment visibility. The goal is not merely to move a package faster; it is to create a repeatable patient-access workflow with fewer avoidable exceptions.

For every delivery channel, establish a failed-delivery protocol. It should cover attempted contact, return-to-pharmacy procedures, product security, temperature assessment, redelivery authorization, and documentation. Teams should know exactly when to quarantine a returned package and when a pharmacist or quality representative must determine disposition.

Protect patient information during fulfillment and delivery

GLP-1 deliveries can involve protected health information when labels, manifests, text messages, delivery applications, or customer-service platforms identify a patient and connect them to healthcare services. Under HIPAA, covered entities and business associates must apply appropriate administrative, physical, and technical safeguards to protected health information.

Operationally, that means using the minimum necessary information for dispatch, limiting access to delivery records, training personnel on privacy expectations, and selecting technology vendors that can support the organization’s compliance obligations. Delivery notifications should be useful without unnecessarily disclosing medication names or diagnoses. Proof-of-delivery workflows should also avoid collecting more information than required.

Privacy controls improve patient trust as well as compliance. A patient is more likely to use pharmacy delivery when the experience is discreet, predictable, and easy to understand.

Measure the metrics that reveal risk early

GLP-1 distribution programs should be managed through a concise operational scorecard. Focus on measures that reveal service, quality, and financial risk:

On-time delivery rate by service level and geography

First-attempt delivery success rate

Temperature excursion or packaging-deviation rate

Returned shipment rate and reason codes

Days on hand by product and dose strength

Fill rate and backorder duration

Product loss from damage, expiration, or failed delivery

Patient complaints and refill interruption rate

Review exceptions, not just averages. A 98% on-time rate can conceal repeated failures in rural areas, certain apartment complexes, or late-day routes. Those patterns are where targeted routing changes, packaging adjustments, or alternate delivery windows deliver the greatest value.

Scale with disciplined partnerships and documented processes

The growth of injectable therapies will continue to test pharmacy supply chains. Organizations that treat the issue as a temporary shortage problem may end up relying on manual workarounds that cannot scale. Those that develop product-specific handling standards, allocation governance, patient-centered delivery design, and measurable quality controls will be better prepared for ongoing demand.

Whether a health system is launching a pharmacy delivery program or strengthening an existing one, the most resilient model connects pharmacy operations to a healthcare-focused transportation partner. OnWay Logistics supports that connection with customized delivery solutions built for the urgency, visibility, and accountability healthcare organizations require.

Frequently Asked Questions

How are GLP-1 medications shipped to patients?

GLP-1 medications are commonly shipped using product-specific temperature-controlled packaging, secure labeling, and delivery methods designed to protect the medication until handoff. Pharmacies should follow the manufacturer’s current storage instructions and use documented procedures for delays, failed deliveries, and suspected temperature excursions.

Do GLP-1 medications need to be refrigerated during delivery?

Many GLP-1 products require refrigeration before dispensing, but shipping requirements differ by product and package configuration. Pharmacies should use the approved prescribing information and manufacturer guidance to determine allowable temperature ranges, transit times, and packaging requirements.

How can pharmacies prevent GLP-1 delivery failures?

Pharmacies can reduce failures by confirming patient availability, offering scheduled delivery windows, using chain-of-custody proof of delivery, and maintaining a documented return process. Reviewing failed-delivery reasons by route and patient location also helps identify recurring issues.